C ase presentation: A 69-year-old woman presented to the hospital with sudden-onset shortness of breath that occurred while standing from a sitting position. The patient was in moderate respiratory distress with a blood pressure of 109/78 mm Hg, heart rate of 109 bpm, and peripheral blood oxygen saturation level of 95% on 3 L of oxygen per nasal cannula. She had an accentuated pulmonary component of the second heart sound, sinus tachycardia on ECG, and an elevated troponin-I level. A large proximal pulmonary embolism was diagnosed by computed tomography. Transthoracic echocardiography demonstrated a right atrial (RA) mass. Transesophageal echocardiography revealed a 3.2-cm thrombus extending from the RA to the left atrium (LA) through a patent foramen ovale (PFO), consistent with impending paradoxical embolism ( 
Overview
Cerebrovascular thromboembolism is responsible annually for Ϸ510 000 ischemic strokes and 139 000 deaths in the United States alone, with expenditure of Ϸ36 billion dollars. 1 Ischemic stroke in the absence of conventional risk factors for cerebral vascular disease indicates that alternative mechanisms for stroke must exist. 2 Indeed, a cause is unidentified or unproven in 40% of all strokes despite comprehensive diagnostic testing. 3 These strokes are known as cryptogenic strokes.
Less common causes of cryptogenic stroke include cardiac tumor, valvular strands (ie, Lambl's excrescences), aortic arch atherosclerotic plaque embolization, or intracardiac venous thromboembolism that is formed in association with structural heart disease. 2, 4, 5 The most common cause of cryptogenic stroke is probably paradoxical embolism due to PFO. 6, 7 Paradoxical embolism, or venous thromboembolism transit from right-to left-sided cardiac chambers, may occur via interventricular, interatrial, or pulmonary arteriovenous malformations. PFO rates are higher in cryptogenic stroke patients than in the general population. In a meta-analysis of 23 case-control studies, the odds ratio for a PFO in cryptogenic stroke patients compared with those with stroke from a known cause was 2.9 (95% confidence interval, 2.1 to 4.0). 3, 8 These findings are similar to those from Handke and colleagues, 9 who prospectively evaluated 503 con-secutive acute stroke patients and observed that compared with stroke from a determined cause, the PFO rate in cryptogenic stroke is significantly greater.
Pathophysiology of Paradoxical Embolism
Normal fetal circulation is dependent on the foramen ovale, which provides a communication for oxygenated blood flow between the RA and LA during lung maturation. 10, 11 At birth, decreased pulmonary vascular resistance and increased LA pressure promote closure of the foramen ovale, although a probepatent PFO is present in 27% of the general population at autopsy. 11 An atrial septal aneurysm (ASA) is a bulging of the atrial septal membrane (eg, septum primum) in the region of the fossa ovalis and is present in Ϸ1% of PFO patients. 12 The precise mechanism of stroke in PFO patients is unresolved but likely occurs due to (1) paradoxical embolism from venous thromboembolism transit through a PFO, (2) PFO-or ASA-induced thrombogenicity, or (3) LA clot formation from atrial arrhythmias that may occur in association with a PFO or ASA.
Risk Stratification of PFO Patients
The annual risk of cryptogenic and recurrent stroke in PFO populations is Ϸ0.1% and 1%, respectively. 13, 14 The influence of ASA on stroke risk in PFO patients remains unresolved. One analysis of patients with PFO plus ASA showed a 4-fold higher recurrent stroke rate over 4 years compared with patients with a PFO alone (19.2% ver-sus 5.6%). 14, 15 A large PFO (Ն4 mm determined by balloon dilation), prominent Chiari's network (ie, sinus venosus remnant), and PFO tunnel length Ͼ14 mm appear to increase the risk of cryptogenic stroke or transient ischemic attack (TIA). 14, 16 The magnitude of right-to-left shunting may positively correlate with the risk of cryptogenic stroke. 17 In the Paradoxical Embolism From Large Veins in Ischemic Stroke (PELVIS) study, cryptogenic stroke was associated with a 5-fold greater probability of pelvic deep vein thrombosis than stroke of determined origin. 18 Similarly, patients with impending paradoxical embolism often present with contemporaneous deep vein thrombosis or pulmonary embolism (Figure and Figure I in the online-only Data Supplement). 19 A genetic predisposition for cryptogenic stroke may exist. In 1 study, the factor V Leiden (G1691A) or prothrombin G20210A gene mutation conferred a 4-fold higher risk of stroke in young PFO patients compared with agematched controls. 20 However, larger epidemiological studies have not confirmed these findings. Therefore, there is insufficient evidence to implicate genetic forms of thrombophilia as independently conferring an increased risk of paradoxical embolism.
Therapeutic Options to Prevent Stroke or TIA in PFO Patients

Primary Prevention
Prevention strategies for a first-time stroke do not differ in patients with respect to PFO status. Some have spec- 
Secondary Prevention With Medical Therapy
Antiplatelet pharmacotherapy with aspirin, aspirin plus extended-release dipyridamole, or clopidogrel is an American Heart Association/American Stroke Association class I indication for the secondary prevention of ischemic stroke. For cardioembolic stroke, warfarin is preferred in select patients. 22 However, owing to inconsistent findings from the largest available clinical trials, optimal medical therapy for prevention of recurrent cryptogenic stroke remains unresolved. Mas and colleagues 15 observed that in 277 consecutive cryptogenic stroke patients (mean age, 40 years) treated with aspirin (300 mg/d), PFO plus ASA but not PFO alone increased the rates of stroke or TIA compared with patients without either of these defects (hazard ratioϭ3.91; 95% confidence interval, 1.59 to 9.59; PϽ0.004). Their results suggested that aspirin monotherapy is adequate in PFO patients but provides insufficient protection for those with a complex interatrial defect such as ASA plus PFO. Homma and colleagues 23 prospectively compared aspirin (325 mg/d) against warfarin (international normalized ratio, 1.8 to 2.4) in 265 cryptogenic stroke patients (mean age, 59 years) enrolled in the randomized, controlled Warfarin-Aspirin Recurrent Stroke Study (WARSS). 24 Irrespective of ASA status (or PFO size), no significant difference in the 2-year rates of stroke or death among patients randomized to either treatment group was observed (aspirin, 14.3% versus warfarin, 12.7%).
Rates of major bleeding from warfarin or aspirin therapy are Ϸ2% and 1%, respectively. Benefits and limita- Percutaneous closure also appears to be effective in patients with PFO plus ASA, particularly when associated with a substantial decrease in shunt severity. Major complication rates associated with device closure occur in Ϸ1.5% of patients, whereas the rate of minor complications such as femoral hematoma and new atrial arrhythmias is Ϸ8%. 26 Additional limitations to device therapy include incomplete device occlusion and insufficient shunt reduction. Furthermore, to prevent clot formation on the surface of the septal occluder before device endothelialization, dual antiplatelet therapy is recommended for 6 months after device implantation (Table 1) .
Surgical PFO closure is comparable in efficacy to percutaneous approaches, with some estimates conferring an annual recurrent stroke rate of 0.34%. 14 Surgical PFO closure as a single indication for sternotomy is uncommon but should be considered in high-risk cryptogenic stroke patients undergoing open heart surgery for other indications or in those for whom successful percutaneous closure is not possible.
Summary
Anticoagulation with either daily aspirin or warfarin is recommended in PFO patients to prevent recurrent stroke. Percutaneous or surgical defect closure is a reasonable treatment choice in patients with a prior cryptogenic stroke and should be considered when the PFO is associated with high-risk features (American Heart Association class IIa indication, level of evidence C). 27 Several ongoing randomized controlled clinical trials evaluating medical and percutaneous therapies for recurrent cryptogenic stroke prevention in PFO patients will provide additional data.
Management of Presented Case
In the case vignette, pulmonary embolectomy was recommended owing to the presence of a RA clot and the patient's high-risk clinical status. The impending paradoxical embolism discovered on intraoperative transesophageal echocardiography was excised, and the PFO was closed surgically. The patient had a full recovery without clinical evidence of stroke or TIA. She was discharged on lifelong warfarin therapy with target international normalized ratio of 2 to 3.
